Evidence map›Paper›PMID 31310845›Full record

ArticleResuscitation2019

Contemporary impacts of a cancer diagnosis on survival following in-hospital cardiac arrest.

Avirup Guha, Benjamin Buck, Michael Biersmith, Sameer Arora, Vedat Yildiz, Lai Wei, Farrukh Awan, Jennifer Woyach, Juan Lopez-Mattei, Juan Carlos Plana-Gomez and 3 more

Abstract read
In one paragraph

Article in Resuscitation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Benefits of cardiopulmonary resuscitation in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  3. Article
  4. Indicators of Clinical Trajectory in Patients With Cancer Who Receive Cardiopulmonary Resuscitation.Journal of the National Comprehensive Cancer Network : JNCCN · 2023
    Article
  5. Article
  6. Article
  7. Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies.Journal of the American Heart Association · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Avirup GuhaDivision of Cardiology, Cardio-Oncology Program, The Ohio State University Medical Center, Columbus, OH, USA; Harrington Heart and Vascular Institute at UH Cleveland Medical Center, Cleveland, OH, USA.
Benjamin BuckDivision of Cardiology, Cardio-Oncology Program, The Ohio State University Medical Center, Columbus, OH, USA.
Michael BiersmithDivision of Cardiology, Cardio-Oncology Program, The Ohio State University Medical Center, Columbus, OH, USA.
Sameer AroraDivision of Cardiology, University of North Carolina, Chapel Hill, NC, USA; Division of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC, USA.
Vedat YildizDivision of Biostatistics, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH, USA.
Lai WeiDivision of Biostatistics, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH, USA.
Farrukh AwanDivision of Hematology, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH, USA.
Jennifer WoyachDivision of Hematology, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH, USA.
Juan Lopez-MatteiDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Juan Carlos Plana-GomezDivision of Cardiology, Baylor College of Medicine, Houston, TX, USA.
Guilherme H OliveiraHarrington Heart and Vascular Institute at UH Cleveland Medical Center, Cleveland, OH, USA.
Michael G FradleyCardio-Oncology Program, Division of Cardiology, University of South Florida and Moffitt Cancer Center, Tampa, FL, USA.
Daniel AddisonDivision of Cardiology, Cardio-Oncology Program, The Ohio State University Medical Center, Columbus, OH, USA. Electronic address: daniel.addison@osumc.edu.

Funding

Translational Training Grant in Experimental TherapeuticsK12CA133250 · NCI · OHIO STATE UNIVERSITY · PI WILLIAM E. CARSON, Rosa Lapalombella · 2008 to 2026
$15.0M
Targeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6M
Improving BTK Directed Therapy for CLLR01CA197870 · NCI · OHIO STATE UNIVERSITY · PI WOYACH, JENNIFER A. · 2015 to 2019
$1.8M
Targeted Therapies and Mechanisms of Resistance in Chronic Lymphocytic LeukemiaK23CA178183 · NCI · OHIO STATE UNIVERSITY · PI WOYACH, JENNIFER A. · 2013 to 2017
$866k
NCI NIH HHS K12 CA133250NCI NIH HHS K23 CA178183NCI NIH HHS R01 CA197870NCI NIH HHS R35 CA197734
6 · The paper itself

Abstract

aimThe objective of this study was to determine whether survival and post-arrest procedural utilization following in-hospital cardiac arrest (IHCA) differ in patients with and without comorbid cancer.

methodsWe retrospectively reviewed all adult (age ≥18 years old) hospital admissions complicated by IHCA from 2003 to 2014 using the National Inpatient Sample (NIS) dataset. Utilizing propensity score matching using age, gender, race, insurance, all hospital level variables, HCUP mortality score, diabetes, hypertension and cardiopulmonary resuscitation use, rates of survival to hospital discharge and post-arrest procedural utilization were compared.

resultsFrom 2003 to 2014, there were a total of 1,893,768 hospitalizations complicated by IHCA, of which 112,926 occurred in patients with history of cancer. In a propensity matched cohort from 2012 to 2014, those with cancer were less likely to survive the hospitalization (31% vs. 46%, p < 0.0001). Following an IHCA, rates of procedural utilization in patients with cancer were significantly less when compared to those without a concurrent malignancy: coronary angiography (4.0% vs. 13.0%), percutaneous coronary intervention (2.2% and 8.0%), targeted temperature management (0.8% vs. 6.0%); p < 0.0001 for all comparisons. This patient population was less likely to have acute coronary syndrome (12.6% vs. 27.0%) or congestive heart failure (24.5% vs. 38.2%); p < 0.0001 for both comparisons. Survival improved in both groups over the study period (p < 0.0001).

conclusionsPatients with a history of cancer who sustain IHCA are less likely to receive post-arrest procedures and survive to hospital discharge. Given the expected rise in the rates of cancer survivorship, these findings highlight the need for broader application of potentially life-saving interventions to lower risk cancer patients who have sustained a cardiac arrest.

Indexed as

Cardiopulmonary ResuscitationHeart ArrestAcute Coronary SyndromeComorbidityFemaleHeart FailureHospitalizationHospital MortalityHumansMaleMiddle AgedNeoplasmsOutcome and Process Assessment, Health CarePatient DischargeProcedures and Techniques UtilizationSurvival AnalysisCancerCardio-oncologyCardiovascular diseaseIn-hospital cardiac arrest

Identifiers

PMID31310845
PMCPMC7881763

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.